John Marotta
CEO Marotta, appointed to Azenta Life Sciences, is expected to cut costs but faces skepticism about his ability to drive growth due to a weak track record.
Sources say Marotta has strong strategic and financial skills but struggles with execution and leadership, contributing to mixed feedback from former colleagues.
Marotta's history of short tenures and underperformance raises doubts about his potential to increase sales at Azenta, suggesting he may focus on cost-cutting instead.
By submitting this form, you are agreeing to ManagementTrack’s Privacy Policy. You can choose to opt out of marketing or advertising emails using the ‘unsubscibe’ link included in our emails.
The best
The best
The best
Our investigative journalists interview the top former colleagues of the CEOs you care about.
Our former buysider analysts summarize the key strengths & weaknesses, past successes & failures, and ability to drive value going forward.
You get access to the actual anonymized transcripts and insights.